使用低profile Altura内移植物系统联合双D形近端支架行血管内动脉瘤修复的初步临床经验
两项前瞻性对照临床研究纳入90例腹主动脉瘤患者,使用低profile(14-F)Altura内移植物系统行EVAR。30天临床成功率为94%,6个月为98%,1年为99%;中位随访12.5个月无动脉瘤破裂、手术转开腹或AAA相关死亡。早期结果提示经适当选择的AAA患者可安全使用该装置,但需进一步临床研究评估其作用。
要点
- Altura系统(14-F,双D形近端支架、肾上固定、髂支从远端向近端释放)在89/90例(99%)中成功植入。
- 30天临床成功率为94%,6个月为98%,1年为99%。
- 中位随访12.5个月无动脉瘤破裂、手术转开腹或AAA相关死亡。
核心结论
- 早期结果提示经适当选择的AAA患者可安全使用Altura内移植物系统治疗,中期结果良好;需进一步临床研究评估该装置在AAA治疗中的作用。
研究设计与样本
- 2011年至2015年,在2项前瞻性对照临床研究的10个临床中心,90例AAA患者(平均年龄72.8±8.3岁,79例男性,平均瘤径53.8±5.7 mm)使用Altura内移植物行EVAR。
主要发现
- 内移植物成功植入89例(99%),唯一失败为早期代装置在插入前输送系统故障所致。
- 30天内1例(1%)死亡,4例再干预(1例I型内漏、2例髂支狭窄、1例内移植物闭塞)。
- 中位随访12.5个月(范围11.5-50.9)期间无动脉瘤破裂、手术转开腹或AAA相关死亡。
- 累积主要不良事件率6个月为3%(3/89),1年为7%(6/89)。
- 2例分别于6.5个月和2.2年行II型内漏弹簧圈栓塞。
关键数值与推荐
- 临床成功定义为无手术相关死亡、I/III型内漏、移位、血栓形成和再干预。
- 主要不良事件包括全因死亡、卒中、截瘫、心肌梗死、呼吸衰竭、肠缺血和失血量≥1000 mL。
临床怎么用
- 原文结论指出,经适当选择的AAA患者可安全使用Altura内移植物系统治疗,中期结果良好;作者认为需进一步临床研究评估该装置在AAA治疗中的作用。
局限性
- 原文结论指出需进一步临床研究评估该装置在AAA治疗中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To report the initial clinical results of endovascular aneurysm repair (EVAR) using the low-profile (14-F) Altura Endograft System, which features a double "D-shaped" stent design with suprarenal fixation and modular iliac components that are deployed from distal to proximal. METHODS: From 2011 to 2015, 90 patients (mean age 72.8±8.3 years; 79 men) with abdominal aortic aneurysm (AAA; mean diameter 53.8±5.7 mm) were treated at 10 clinical sites in 2 prospective, controlled clinical studies using the Altura endograft. Outcomes evaluated included mortality, major adverse events (MAEs: all-cause death, stroke, paraplegia, myocardial infarction, respiratory failure, bowel ischemia, and blood loss ≥1000 mL), and clinical success (freedom from procedure-related death, type I/III endoleak, migration, thrombosis, and reintervention). RESULTS: Endografts were successfully implanted in 89 (99%) patients; the single failure was due to delivery system malfunction before insertion in the early-generation device. One (1%) patient died and 4 patients underwent reinterventions (1 type I endoleak, 2 iliac limb stenoses, and 1 endograft occlusion) within the first 30 days. During a median follow-up of 12.5 months (range 11.5-50.9), there were no aneurysm ruptures, surgical conversions, or AAA-related deaths. The cumulative MAE rates were 3% (3/89) at 6 months and 7% (6/89) at 1 year. Two patients underwent coil embolization of type II endoleaks at 6.5 months and 2.2 years, respectively. Clinical success was 94% (84/89) at 30 days, 98% (85/87) at 6 months, and 99% (82/83) at 1 year. CONCLUSION: Early results suggest that properly selected AAA patients can be safely treated using the Altura Endograft System with favorable midterm outcome. Thus, further clinical investigation is warranted to evaluate the role of this device in the treatment of AAA.
引用
- Krievins D, Krämer A, Savlovskis J, et al. Initial Clinical Experience Using the Low-Profile Altura Endograft System With Double D-Shaped Proximal Stents for Endovascular Aneurysm Repair. J Endovasc Ther. 2018. PMID: 29673298. doi:10.1177/1526602818771973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。